None

Meloxicam and rizatriptan combination tablets (meloxicam and rizatriptan) are a combination drug used to treat acute attacks of migraine in adults, with the trade name Symbravo. The drug was developed by Axsome Therapeutics, Inc., an American original drug manufacturer. It was approved for marketing in the United States on January 30, 2025, but has not yet been approved in the European Union and China. Its dosage form is tablets, each tablet contains 20 mg meloxicam and 10 mg rizatriptan, and is usually packaged in a box of 9 tablets, with a validity period of 6 months. As a new compound preparation, it combines two pharmaceutical ingredients with different mechanisms, aiming to provide a more comprehensive symptom relief solution for migraine patients.

From the perspective of pharmacological effects, meloxicam is a non-steroidal anti-inflammatory drug (NSAID). It mainly reduces the synthesis of prostaglandins by inhibiting cyclooxygenase (COX-1 and COX-2), thereby exerting analgesic, anti-inflammatory and antipyretic effects. Prostaglandins are important mediators of inflammation and pain, and their reduction can help alleviate the inflammatory response that accompanies migraines. Rizatriptan is a 5-hydroxytryptamine receptor agonist that can specifically act on the 5-HT1B/1D receptors in intracranial blood vessels and the trigeminal nervous system to relieve migraine symptoms by regulating vasomotion and inhibiting neuroinflammation. The synergistic effect of these two components allows the drug to intervene in the pathological process of migraine from different pathways, and may theoretically have more therapeutic advantages than single-component drugs.

The indications of this drug are clearly for acute attacks of migraine with or without aura in adults, and the scope of use is limited. It is only suitable for patients with confirmed migraine headaches and is not intended for preventive treatment of migraines or for the treatment of cluster headaches. The recommended dose is to take one tablet orally during each migraine attack. The maximum daily dose is one tablet. Do not exceed the dosage. It should be noted that the safety of treating more than 7 migraines within 30 consecutive days has not been established, so patients should reasonably control the frequency of medication under the guidance of a doctor to achieve the best therapeutic effect while reducing potential risks.
When using this drug, special attention should be paid to its storage conditions and drug interactions. It should be kept in an environment of 20°C-25°C during storage, and is allowed to fluctuate within the range of 15°C-30°C for a short period of time. This drug interacts with a variety of drugs, especially when combined with anticoagulants, antihypertensives, diuretics, etc., which may affect the efficacy or increase the risk of adverse reactions. For example, concomitant use with ACE inhibitors or ARB drugs may reduce the antihypertensive effect, and concomitant use with lithium or methotrexate may lead to an increase in blood drug concentrations. Therefore, patients should inform their doctors in detail about all medications they are taking before taking them to avoid potential drug interactions.
For special groups, this drug should be used with extreme caution. Safety data for pregnant women, lactating women, children and the elderly are limited and should be used after strict evaluation by a physician. It is contraindicated in patients with cardiovascular disease, hepatic and renal insufficiency, or allergies to NSAIDs and triptans. In addition, adverse reactions such as dizziness and fatigue may occur during medication, and patients should avoid driving or operating precision instruments. Overall, meloxicam and rizatriptan combination tablets provide a new option for the treatment of migraine, but patients need to fully understand its properties and use it under professional guidance to ensure the safety and effectiveness of the medication.
Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215431s000lbl.pdf